Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.